MDMA (Ecstasy) neurotoxicity: Assessing and communicating the risks

Lancet

Volumn 355, Issue 9217, 2000, Pages 1818-1821

  Boot, Brendon P ^a,c   McGregor, Iain S ^b   Hall, Wayne ^c  

^a University of Sydney   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; 5 HYDROXYINDOLEACETIC ACID; DEXFENFLURAMINE; ILLICIT DRUG; SEROTONIN; SEROTONIN AGONIST; TRYPTOPHAN;

COGNITIVE DEFECT; DEPRESSION; DIAGNOSTIC IMAGING; DRUG ABUSE PATTERN; HEALTH EDUCATION; HUMAN; IMPULSIVENESS; NEUROTOXICITY; NONHUMAN; NOTE; PRIORITY JOURNAL; PROVOCATION TEST; RISK ASSESSMENT; TOXICITY TESTING;

EID: 0034690772     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)02276-5     Document Type: Note

References (47)

1. Cohen R.S. The love drug: marching to the beat of ecstasy. 1998;Haworth Medical Press, New York.
2. Saunders N., Doblin R. Ecstasy: dance, trance and transformation. 1996;Quick American Archives, San Francisco.
3. Solowij N., Hall W., Lee N. Recreational MDMA use in Sydney. a profile of 'Ecstasy' users and their experiences with the drug Br J Addiction. 87:1992;1161-1172.
4. Hegadoren K.M., Baker G.B., Bourin M. 3,4-Methylenedioxy analogues of amphetamine. defining the risks to humans Neurosci Biobehav Rev. 23:1999;539-553.
5. Parrott A.C., Lasky J. Ecstasy (MDMA) effects upon mood and cognition. before, during and after a Saturday night dance Psychopharmacology. 139:1998;261-268.
6. Hatzidimitriou G., McCann U.D., Ricaurte G.A. Altered serotonin innervation patterns in the forebrain of monkeys treated with (+/-)3,4-methylenedioxymethamphetamine seven years previously. factors influencing abnormal recovery J Neurosci. 19:1999;5096-5107.
7. Fischer C., Hatzidimitriou G., Wlos J., Katz J., Ricaurte G.A. Reorganization of ascending 5-HT axon projections in animals previously exposed to the recreational drug (+/-)3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy"). J Neurosci. 15:1995;5476-5485.
8. Colado M.I., O'Shea E., Granados R., Esteban B., Martin A.B., Green A.R. Studies on the role of dopamine in the degeneration of 5-HT nerve endings in the brain of Dark Agouti rats following 3,4-methylenedioxymethamphetamine (MDMA or 'ecstasy') administration. Br J Pharmacol. 126:1999;911-924.
9. Scheffel U., Szabo Z., Mathews W.B.et al. In vivo detection of short- and long-term MDMA neurotoxicity. a positron emission tomography study in the living baboon brain Synapse. 29:1998;183-192.
10. Ricaurte G.A., DeLanney L.E., Irwin I., Langston J.W. Toxic effects of MDMA on central serotonergic neurons in the primate. importance of route and frequency of drug administration Brain Res. 446:1988;165-168.
11. Chappell W.R., Mordenti J. Extrapolation of toxicological and pharmacological data from animals to humans. Testa B. Advances in drug research. 1991;Academic Press, London.
12. Sprague J.E., Everman S.L., Nichols D.E. An integrated hypothesis for the serotonergic axonal loss induced by 3,4-methylenedioxymethamphetamine. Neurotoxicology. 19:1998;427-441.
13. Topp L., Hando J., Dillon P., Roche A., Solowij N. Ecstasy use in Australia. patterns of use and associated harm Drug Alcohol Dep. 55:1999;105-115.
14. Malberg J.E., Seiden L.S. Small changes in ambient temperature cause large changes in 3,4-methylenedioxymethamphetamine (MDMA)-induced serotonin neurotoxicity and core body temperature in the rat. J Neurosci. 18:1998;5086-5094.
15. McCann U.D., Ridenour A., Shaham Y., Ricaurte G.A. Serotonin neurotoxicity after (+/-)3,4-methylenedioxymethamphetamine (MDMA; "Ecstasy"). a controlled study in humans Neuropsychopharmacology. 10:1994;129-138.
16. Peroutka S.J., Pascoe N., Faull K.F. Monamine metabolites in the cerebrospinal fluid of recreation users of 3,4-methylenedioxymethamphetamine (MDMA; "Ecstasy"). Res Commun Subst Abuse. 8:1987;125-138.
17. McCann U.D., Mertl M., Eligulashvili V., Ricaurte G.A. Cognitive performance in (+/-)3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") users. a controlled study Psychopharmacology. 143:1999;417-425.
18. Bolla K.I., McCann U.D., Ricaurte G.A. Memory impairment in abstinent MDMA ("Ecstasy") users. Neurology. 51:1998;1532-1537.
19. Ricaurte G.A., Finnegan K.T., Irwin I., Langston J.W. Aminergic metabolites in cerebrospinal fluid of humans previously exposed to MDMA. preliminary observations Ann NY Acad Sci. 600:1990;699-708.
20. McCann U.D., Eligulashvili V., Mertl M., Murphy D.L., Ricaurte G.A. Altered neuroendocrine and behavioral responses to m-chlorophenylpipcrazine in 3,4-methylenedioxymethamphetamine (MDMA) users. Psychopharmacology. 147:1999;56-65.
21. Gerra G., Zaimovic A., Giucastro G.et al. Serotonergic function after (+/-)3,4-methylenedioxyamphetamine ('Ecstasy') in humans. Int Clin Psychopharm. 13:1998;1-9.
22. Gerra G., Zaimovic A., Ferri M.et al. Long-lasting effects of (+/-)3,4-methylenedioxymethamphetamine (ecstasy) on serotonin system function in humans. Biol Psychiatry. 47:2000;127-136.
23. Price L.H., Ricaurte G.A., Krystal J.H., Heninger G.R. Neuroendocrine and mood responses to intravenous L-tryptophan in 3,4-methylenedioxymethamphetamine (MDMA) users. preliminary observations Arch Gen Psychiatry. 46:1989;20-22.
24. McCann U.D., Szabo Z., Scheffel U., Dannals R.F., Ricaurte G.A. Positron emission tomographic evidence of toxic effect of MDMA (Ecstasy) on brain serotonin neurons in human beings. Lancet. 352:1998;1433-1437.
25. Semple D.M., Ebmeier K.P., Glabus M.F., O'Carroll R.E., Johnstone E.C. Reduced in vivo binding to the serotonin transporter in the cerebral cortex of MDMA ('ecstasy') users. Br J Psychiatr. 175:1999;63-69.
26. Reed L.J., Winstock A., Cleare A.J., McGuire P. Toxic effect of MDMA on brain serotonin neurons. Lancet. 353:1999;1268.
27. Obrocki J., Buchert R., Vaterlein O., Thomasius R., Beyer W., Schiemann T. Ecstasy - long-term effects on the human central nervous system revealed by positron emission tomography. Br J Psychiatr. 175:1999;186-188.
28. Dafters R.I., Duffy F., O'Donnell P.J., Bouquet C. Level of use of 3,4-methylenedioxymethamphetamine (MDMA or Ecstasy) in humans correlates with EEG power and coherence. Psychopharmacology. 145:1999;82-90.
29. Frederick D.L., Paule M.G. Effects of MDMA on complex brain function in laboratory animals. Neurosci Biobehav Rev. 21:1997;67-78.
30. Parrott A.C., Lees A., Garnham N.J., Jones M., Wesnes K. Cognitive performance in recreational users of MDMA or Ecstasy - evidence for memory deficits. J Psychopharmacol. 12:1998;79-83.
31. Schifano F., Difuria L., Forza C., Minicuci N., Bricolo R. MDMA (Ecstasy) consumption in the context of polydrug abuse - a report on 150 patients. Drug Alcohol Dep. 52:1998;85-90.
32. Soubrie P. Reconciling the role of central serotonin neurons in human and animal behaviour. Behav Brain Sci. 9:1986;319-364.
33. Morgan M.J. Recreational use of Ecstasy (MDMA) is associated with elevated impulsivity. Neuropsychopharmacology. 19:1998;252-264.
34. Staley J.K., Malison R.T., Innis R.B. Imaging of the serotonergic system. interactions of neuroanatomical and functional abnormalities of depression Biol Psychiatr. 44:1998;534-549.
35. Curran H.V., Travill R.A. Mood and cognitive effects of +/-3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy'). week-end 'high' followed by mid-week low Addiction. 92:1997;821-831.
36. Marston H.M., Reid M.E., Lawrence J.A., Olverman H.J., Butcher S.P. Behavioural analysis of the acute and chronic effects of MDMA treatment in the rat. Psychopharmacology. 144:1999;67-76.
37. Morgan M.J. Memory deficits associated with recreational use of "Ecstasy" (MDMA). Psychopharmacology. 141:1999;30-36.
38. Gijsman H.J., Verkes R.J., van Gerven J.M.A., Cohen A.F. MDMA study. Neuropsychopharmacology. 21:1999;597.
39. Vollenweider F.X., Gamma A., Liechti M., Huber T. Is a single dose of MDMA harmless? Neuropsychopharmacology. 21:1999;598-600.
40. Brody S., Krause C., Veit R., Rau H. Cardiovascular autonomic dysregulation in users of MDMA (Ecstasy). Psychopharmacology. 136:1998;390-393.
41. Dafters R.I., Lynch E. Persistent loss of thermoregulation in the rat induced by 3,4-methylenedioxymethamphetamine (MDMA or Ecstasy) but not by fenfluramine. Psychopharmacology. 138:1998;207-212.
42. Allen R.P., McCann U.D., Ricaurte G.A. Persistent effects of (+/-)3,4-methylenedioxymethamphetamine (MDMA, Ecstasy) on human sleep. Sleep. 16:1993;560-564.
43. McElhatton P.R., Bateman D.N., Evans C., Pughe K.R., Thomas S.H.L. Congenital anomalies after prenatal ecstasy exposure. Lancet. 354:1999;1441-1442.
44. McCann U.D., Seiden L.S., Rubin L.J., Ricaurte G.A. Brain serotonin neurotoxicity and primary pulmonary hypertension from fenfluramine and dexfenfluramine. a systematic review of the evidence JAMA. 278:1997;666-672.
45. McCann U.D., Ricaurte G.A. Reinforcing subjective effects of (+/-)3,4-methylenedioxymethamphetamine ("Ecstasy") may be separable from its neurotoxic actions. clinical evidence J Clin Psychopharm. 13:1993;214-217.
46. Feachem R.G.A. Valuing the past ... investigating in the future: evaluation of the National HIV/AIDS Strategy 1993-94 to 1995-96. 1995;Australian Government Publishing Service, Canberra.
47. Calafat A., Stocco P., Medes F.et al. Characteristics and social representation of Ecstasy in Europe. 1998;IREFREA, Valencia.